Previous 10 | Next 10 |
home / stock / nevpf / nevpf news
NeuroVive Pharmaceutical AB ( OTCQX:NEVPF ): Q2 GAAP EPS of -SEK0.14. More news on: NeuroVive Pharmaceutical AB, Neurovive Pharmaceutical AB ADR, Earnings news and commentary, Healthcare stocks news, , Read more ...
Focus on genetic mitochondrial diseases STOCKHOLM , Aug. 21, 2019 /PRNewswire/ -- Important events April – June The US Food and Drug Administration, FDA, approves NeuroVive's IND (Investigational New Drug) application, enabling clinical studies in the US with the ...
LUND, Sweden , Aug. 20, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the company will host a Capital Markets Day in Stockholm on 9 October, 2019 , for investors, analysts and media. Presentations wil...
LUND, Sweden , July 27, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the company's candidate drug NeuroSTAT, in development for treatment of moderate to severe traumatic brain injury, TBI, has received Fast Tra...
LUND, Sweden , 4 July 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the company has initiated the second part in its ongoing Phase Ia/b clinical study with KL1333, NeuroVive's candidate drug for chronic tre...
STOCKHOLM , May 21, 2019 /PRNewswire/ -- Important events January- March 2019 NeuroVive enrolls first subject in its KL1333 phase Ia/b clinical study. NeuroVive is supplied with approximately MSEK 99.0 in share issue proceeds. NeuroVive receives SEK 28.2 Million in a directed ...
LUND, Sweden , May 10, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the US Food and Drug Administration, FDA, has approved NeuroVive's IND (Investigational New Drug) application, enabling clinical studies in...
LUND, Sweden , 25 March 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the English version of the Annual report for 2018 is now available on the company's website www.neurovive.com . This information...
LUND, Sweden , March 7, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF ) t oday announced that the company has successfully conducted a directed new issue of shares, which has raised proceeds to NeuroVive of SEK 28.2 mill...
LUND, Sweden , Feb. 21, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company has entered into an exclusive agreement to license and supply two of its first generation of succinate/malonate prodrugs a...
News, Short Squeeze, Breakout and More Instantly...
Neurovive Pharm Ab Ord Company Name:
NEVPF Stock Symbol:
OTCMKTS Market:
Neurovive Pharm Ab Ord Website:
- Independent committee confirms FALCON study is powered for potential success with both alternative endpoints passing futility- -Committee confirms strong safety profile of KL1333- - Abliva to host conference call and webcast on Friday 19 July at 4:30 pm CET / 10:30 am ...
LUND, Sweden, May 13, 2024 (GLOBE NEWSWIRE) -- Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that it will host a virtual KOL event on Tuesday, May 21, 2024 at 10:00 AM ET / 4:00 PM ...
Abliva AB (publ) (NEVPF) is expected to report for Q4 2023